Recent studies reveal significant health risks and weight regain associated with the discontinuation of GLP-1 medications such as Ozempic and Wegovy. Patients who stop taking these drugs are at an increased risk of heart attack, stroke, and rapid weight gain, with findings indicating that up to 60% of lost weight may be regained within a year of cessation. The cardiovascular benefits experienced during treatment also diminish quickly after stopping, often leading patients to restart their medications or explore alternatives. Experts warn that while these weight-loss drugs can offer substantial short-term benefits, the long-term strategy requires careful consideration of potential health implications upon discontinuation.